SCHEMBL2802391

SCHEMBL2802391

Cc1ccc(C2CCN(C(=O)c3cnc4c(C(=O)NS(C)(=O)=O)cnn4c3NCc3ccccc3)CC2)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.41
THRB P10828 2/20 0.41
TDP1 Q9NUW8 1/20 0.40
STAT6 P42226 1/20 0.40
ENPP2 Q13822 1/20 0.39
TP53 P04637 3/20 0.39
MAPT P10636 1/20 0.39
SPR P35270 2/20 0.38
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
POLB P06746 1/20 0.37
TUBB4A P04350 1/20 0.37
TUBB P07437 1/20 0.37
TUBA3C P0DPH7 1/20 0.37
TUBA1B P68363 1/20 0.37
TUBA4A P68366 1/20 0.37
TUBB4B P68371 1/20 0.37
TUBB3 Q13509 1/20 0.37
TUBB2A Q13885 1/20 0.37
TUBB8 Q3ZCM7 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2799687 0.95 STAT6 (0.40) SMN1; SMN2THRBSTAT6ENPP2SPR
SCHEMBL2800864 0.93 CCR1 (0.42) SMN1; SMN2THRBSTAT6ENPP2TP53
SCHEMBL2802693 0.93 TP53 (0.41) SMN1; SMN2STAT6ENPP2TP53MAPT
SCHEMBL2803544 0.92 TPSAB1 (0.40) SMN1; SMN2THRBTDP1TP53MAPT
SCHEMBL2798553 0.91 THRB (0.37) SMN1; SMN2THRBTDP1STAT6ENPP2
SCHEMBL2798414 0.91 STAT6 (0.43) SMN1; SMN2THRBTDP1STAT6ENPP2
SCHEMBL2802186 0.89 VNN1 (0.43) ALDH1A1HSD17B10HPGDKDM4E
SCHEMBL2801027 0.89 RBP4 (0.40) SMN1; SMN2THRBTDP1TP53MAPT
SCHEMBL2802824 0.89 STAT6 (0.39) SMN1; SMN2THRBSTAT6ENPP2SPR
SCHEMBL2804072 0.89 STAT6 (0.41) SMN1; SMN2THRBSTAT6ENPP2SPR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2206714-B1 AGENT FOR PREVENTION AND/OR TREATMENT OF SKIN DISEASES KYOWA HAKKO KIRIN CO LTD (JP) 2015-01-21 EP disclosed
US-8729264-B2 Agent for prevention and/or treatment of skin diseases KYOWA HAKKO KIRIN CO., LTD. (JP) 2014-05-20 US disclosed
US-20100256134-A1 AGENT FOR PREVENTION AND/OR TREATMENT OF SKIN DISEASES KYOWA HAKKO KIRIN CO., LTD. (JP) 2010-10-07 US disclosed
EP-2206714-A1 AGENT FOR PREVENTION AND/OR TREATMENT OF SKIN DISEASES Kyowa Hakko Kirin Co., Ltd. (JP) 2010-07-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256134-A1 AGENT FOR PREVENTION AND/OR TREATMENT OF SKIN DISEASES TYR, CUTA, SERPINB1 SMN1; SMN2 2769/4885THRB 4546/4885TDP1 1594/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.